PDT Partners LLC Has $2.60 Million Stake in DexCom, Inc. (NASDAQ:DXCM)

PDT Partners LLC cut its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 36.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 33,379 shares of the medical device company's stock after selling 18,911 shares during the period. PDT Partners LLC's holdings in DexCom were worth $2,596,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Versant Capital Management Inc acquired a new position in shares of DexCom in the 4th quarter valued at $25,000. Private Trust Co. NA grew its stake in DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after acquiring an additional 245 shares during the period. Optiver Holding B.V. acquired a new position in shares of DexCom in the 4th quarter valued at approximately $33,000. TD Private Client Wealth LLC increased its stake in DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after purchasing an additional 167 shares in the last quarter. Finally, Larson Financial Group LLC raised its holdings in DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after buying an additional 137 shares during the period. Institutional investors own 97.75% of the company's stock.

Analysts Set New Price Targets

DXCM has been the subject of several research analyst reports. Piper Sandler reduced their price target on shares of DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a report on Friday. Cfra Research upgraded DexCom to a "hold" rating in a report on Friday, March 21st. Morgan Stanley boosted their price target on DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a report on Friday, February 14th. Robert W. Baird decreased their price target on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research note on Friday. Finally, Canaccord Genuity Group boosted their price objective on shares of DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research report on Friday. Five investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, DexCom has an average rating of "Moderate Buy" and a consensus target price of $99.22.

DexCom Stock Performance

DXCM traded up $11.36 during trading hours on Friday, reaching $81.62. The company's stock had a trading volume of 10,694,799 shares, compared to its average volume of 4,256,454. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The company's 50-day moving average is $71.46 and its 200-day moving average is $76.77. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $132.26. The firm has a market cap of $32.00 billion, a PE ratio of 57.08, a price-to-earnings-growth ratio of 2.30 and a beta of 1.50.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The company had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.02 billion. DexCom had a return on equity of 30.14% and a net margin of 14.29%. The business's quarterly revenue was up 12.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.32 EPS. On average, equities analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Activity

In other DexCom news, COO Jacob Steven Leach sold 14,076 shares of the stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $990,668.88. Following the transaction, the chief operating officer now owns 313,497 shares in the company, valued at $22,063,918.86. This represents a 4.30 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Jereme M. Sylvain sold 7,000 shares of DexCom stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $73.83, for a total transaction of $516,810.00. Following the completion of the sale, the executive vice president now owns 135,482 shares of the company's stock, valued at approximately $10,002,636.06. The trade was a 4.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 66,926 shares of company stock valued at $4,734,384. 0.32% of the stock is owned by insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.